title: [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
authors.affiliation: Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum, Paracelsus Medizinische Privatuniversität Salzburg.
authors.forename: S P
authors.initials: SP
authors.lastname: Gampenrieder
mesh_terms: D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D049109:Cell Proliferation; D017024:Chemotherapy, Adjuvant; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000235:genetics; D009376:Neoplasms, Hormone-Dependent / Q000145:classification / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D059467:Transcriptome / Q000235:genetics*
chemical_list: D005819:Genetic Markers; D019394:Ki-67 Antigen; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human